METHOD FOR COLLECTING DATA FOR PREDICTING ADMINISTRATION EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR TO CANCER PATIENT
To provide a novel technique of predicting administration effectiveness of an immune checkpoint inhibitor.SOLUTION: A method for collecting data for predicting administration effectiveness of an immune checkpoint inhibitor to a cancer patient, which includes a process of measuring an expression leve...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng ; jpn |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To provide a novel technique of predicting administration effectiveness of an immune checkpoint inhibitor.SOLUTION: A method for collecting data for predicting administration effectiveness of an immune checkpoint inhibitor to a cancer patient, which includes a process of measuring an expression level of a marker gene or a marker protein in a biological sample derived from the cancer patient. In the method, the marker gene or marker protein includes NELL2 gene or protein, AMICA1 gene or protein, CLEC11A gene or protein, CLECL1 gene or protein or CMTM7 gene or protein, the expression level is data for predicting the effectiveness, and the fact that the expression level is higher than a reference value indicates that administration of the immune checkpoint inhibitor to the cancer patient is effective.SELECTED DRAWING: None
【課題】免疫チェックポイント阻害薬の投与の有効性を予測する新たな技術を提供する。【解決手段】癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法であって、前記癌患者由来の生体試料における、マーカー遺伝子又はマーカータンパク質の発現量を測定する工程を含み、前記マーカー遺伝子又はマーカータンパク質が、NELL2遺伝子若しくはタンパク質、AMICA1遺伝子若しくはタンパク質、CLEC11A遺伝子若しくはタンパク質、CLECL1遺伝子若しくはタンパク質又はCMTM7遺伝子若しくはタンパク質を含み、前記発現量が前記有効性を予測するためのデータであり、前記発現量が基準値よりも高いことが、前記癌患者への前記免疫チェックポイント阻害薬の投与が有効であることを示す、方法。【選択図】なし |
---|